Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Regorafenib and Pembrolizumab in Metastatic Colorectal Cancer Patients in 3rd and 4th Line Setting

NCT03657641 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT03657641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03657641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Regorafenib and Pembrolizumab in Metastatic Colorectal Cancer Patients in 3rd and 4th Line Setting
Lead sponsor
University of Southern California
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 21, 2019
Completion date
December 31, 2027
Enrollment
73 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, colorectal cancer metastatic